Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,721,904 papers from all fields of science
Search
Sign In
Create Free Account
Mebaral
Known as:
Sanofi Brand of Mephobarbital
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Mephobarbital
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1975
1975
Single extraction GLC analysis of six commonly prescribed antiepileptic drugs.
Ritz Dp
1975
Corpus ID: 208201810
: A simple gas-liquid chromatographic technique for the quantitation of ethosuximide (Zarontin), methsuximide (Celontin…
Expand
1975
1975
Single extraction GLC analysis of six commonly prescribed antiepileptic drugs.
D. Ritz
Clinical toxicology
1975
Corpus ID: 29438044
A simple gas-liquid chromatographic technique for the quantitation of ethosuximide (Zarontin), methsuximide (Celontin…
Expand
1959
1959
Effects of thorazine and mebaral on alertness in psychotic patients.
B. Rosner
,
L. Ameen
,
P. A. Kolers
Current Therapeutic Research
1959
Corpus ID: 30735050
1953
1953
THE USE OF MEBARAL IN THE TREATMENT OF CHRONIC ALCOHOLISM
J. Smith
,
W. T. Brown
Journal of Nervous and Mental Disease
1953
Corpus ID: 32558456
1952
1952
Successful treatment of hyperhidrosis with mephobarbital; report of two cases.
W. G. Scanlon
Journal of the American Medical Association
1952
Corpus ID: 45268421
Hyperhidrosis is an annoying and frequently embarassing symptom that is difficult to control. In the first case to be reported…
Expand
1951
1951
Drug effects on the results of minimal cortical stimulation.
J. A. Whieldon
,
A. van Harreveld
Electroencephalography and Clinical…
1951
Corpus ID: 34804533
1942
1942
Mebaral in the Treatment of Epilepsy
B. Cohen
,
A. Myerson
1942
Corpus ID: 57894144
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE